Clinical Trial Update: Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I) [Phase 2]

View source ↗

Summary

The National Cancer Institute provides an update on the phase 2 MATCH subprotocol evaluating taselisib (GDC-0032) in cancers with PIK3CA genetic alterations. Th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Multiple Myeloma
• Solid Tumors

Drugs mentioned

• Taselisib (GDC-0032)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-12-28